<DOC>
	<DOC>NCT00116467</DOC>
	<brief_summary>The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).</brief_summary>
	<brief_title>Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Initial diagnosis of de novo AML with no preexisting hematologic dysplasia for more than 3 months. No prior therapy except leukapheresis or less than 72 hours of hydroxyurea. Prior myelodysplastic disorder, or treatmentrelated leukemia. Prior myeloproliferative disease. Acute promyelocytic leukemia (APL). Prior chemotherapy for a malignant or nonmalignant disorder.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>GVAX</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Autologous</keyword>
</DOC>